Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for prevention of microvascular injury during PCI in NSTEACS
ACTRN12615000709549Phase 3Recruiting
- Sponsor
- Prince of Wales Hospital
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) and Myocardial injury comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Peri-procedural change in index of microvascular resistance. Started Feb 2015; status: recruiting.
02
Drugs
ambrisentan
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)Myocardial injury
Beyond the preview
Go deeper on ACTRN12615000709549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000709549.